Please login to the form below

Not currently logged in
Email:
Password:

Huntingdon's disease

This page shows the latest Huntingdon's disease news and features for those working in and with pharma, biotech and healthcare.

Ionis and Roche gain PRIME status for Huntingdons disease candidate

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval. Ionis and Roche’s pipeline drug for Huntingdon’s disease has been granted special ‘PRIME’ status by the European Medicines Agency (EMA). ... s disease to regulatory approval faster.

Latest news

  • EMA hands UniQure orphan status first in Huntington's EMA hands UniQure orphan status first in Huntington's

    Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure’s candidate fit the bill, not least because there are no currently approved

  • Roche signs Parkinson's deal with Prothena Roche signs Parkinson's deal with Prothena

    Antibody development agreement is worth up to $600m. Roche has upped its efforts in Parkinson's disease by agreeing to research new antibodies with the US biotech Prothena. ... This technology was also a key aspect of a recent deal with Isis to tackle

  • Roche and Isis in $392m deal to research drugs for brain disorder Roche and Isis in $392m deal to research drugs for brain disorder

    The unmet medical need for Huntingdon's disease is compounded by its severity,  with patients enduring progressive loss of both mental faculties and physical control. ... foundation exclusively dedicated to the development of therapies that slow the

  • Bouncing back

    The deal should speed up new treatments for Huntingdon's disease, Parkinson's disease and for strokes. ... attention to incidents of vision loss among patients taking GSK's Levitra, Pfizer's Viagra and Lilly's Cialis.

  • Malcolm's Market Eye: 7 to 13 July 2007

    The market for ReNeuron's treatment is large with some 12m stroke survivors in Japan, the US and the EU, with nearly one third needing continual nursing care. ... ReNeuron is also focusing on inherited Huntingdon's disease and type 1 diabetes needing

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...